viewFaron Pharmaceuticals Ltd

Faron explores options for drug ingredients manufacturing

The manufacturing process for its lead drug candidate requires "significant" upgrade to receive approval by the authorities

Faron Pharmaceuticals Ltd - Faron explores options for drug ingredients manufacturing
German producer Rentschler Biopharma issued contract termination notice

Faron Pharmaceuticals Ltd (LON:FARN) is exploring options for ingredients manufacturing of Traumakine, its lead drug candidate.

The drug company received a contract termination notice from German producer Rentschler Biopharma, which was providing the active pharmaceutical ingredient (API) manufacturing.

READ: Faron Pharma in talks to find partner for lead cancer drug

The decision was related to the “significant” upgrade to the manufacturing process that would be required to receive approval by the European and US authorities to produce the drug.

Faron said this termination has no impact on the ongoing clinical advice process, as it focuses on a clinical study structure for Traumakine, which is used to treat acute respiratory distress.

Studies in the development of Traumakine revealed it requires a design to avoid administering in combination with corticosteroids, which Faron has already submitted for feedback.

Once the design is approved, the AIM-listed firm will carry on discussions for third party funding, as announced last week.

Shares were down 2.79% to 97.7p at noon.


Quick facts: Faron Pharmaceuticals Ltd

Price: 291 GBX

Market: AIM
Market Cap: £136.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read